The need for advanced chronotherapeutics is not only necessitated by the strong association between certain diseases, e.g. asthma, angina, and cancer, and biological rhythms,71, –73 but a greater therapeutic efficacy is also achieved when therapeutic compounds aim to mimic the pulsatile release of endogenous peptides, e.g. insulin, gonadotropin-releasing hormone (GnRH), and somatostatin.74 Insulin is a particularly interesting example. The gene discussed is INS; the disease is angina pectoris.